BioFire Defense Part...
FDA Clearance and CL...
11th May 2023 Product update: bioMérieux (Clinical Diagnostics)
US FDA CLIA-waiver for BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini Uses Multiplex PCR
A Clinical Laboratory Improvement Amendments (CLIA) waiver has been granted to bioMérieux, for the quick and precise BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini with multiplex PCR. This is in addition to the 510(k) clearance obtained in April 2023.
The COVID-19 pandemic has illustrated the need for medical professionals to have quick-acting diagnostic tests on hand as close to the patient as is practical. The second multiplex PCR-based test approved for use on the BIOFIRE® SPOTFIRE® System is the BIOFIRE® SPOTFIRE® R Panel Mini.
In February 2023, this system and its BIOFIRE® SPOTFIRE® Respiratory Panel with 15 targets received FDA clearance and CLIA waivers.
Approximately 15 minutes are needed for the new BIOFIRE® SPOTFIRE® R Panel Mini to identify five of the most prevalent viruses that cause upper respiratory tract infections:
- SARS-CoV-2,
- Influenza A and B,
- Respiratory Syncytial Virus (RSV),
- and Rhinovirus.
Tags:
Date Published: 11th May 2023
Source article link: View
Note: This content has been edited by a rapidmicrobiology staff writer for style and content.
BioFire Defense Partners With BARDA
FDA Clearance and CLIA-waiver for
bioMérieux (Clinical Diagnostics)
Address:
Marcy L'Etoile
France
Related news from bioMérieux (Clinical Diagnostics)
- BIOFIRE® SPOTFIRE® Respiratory/Sore Throat Panel Mini Receives FDA Special Clearance and CLIA Waiver
- bioMérieux's AST System VITEK® REVEAL Achieves FDA 510(k) Clearance
- FDA Clearance and CLIA-waiver for bioMerieux's BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel
- BioFire Defense Partners With BARDA
- FDA Clearance and CLIA-waiver for Fast and Innovative BIOFIRE® SPOTFIRE® POC System
- MAESTRIA™, a New Generation Microbiology Middleware Optimizes Laboratory Workflow
- VIDAS® KUBE™ - the Next-generation VIDAS® System Receives CE Marking
- FDA Breakthrough Device Designation for SPECIFIC REVEAL® Rapid AST System
- Added Medical Value with Urine Sample Results Up to 8 Hours Faster
- bioMérieux to Distribute Specific Diagnostics’ REVEAL Rapid AST System in Europe
- Enhanced BIOFIRE® Blood Culture Identification 2 (BCID2) Panel Submitted for FDA Clearance
- Spotlight on Antimicrobial Stewardship with bioMérieux
- New FDA Clearance for VITEK® MS: Expanded ID for Challenging Pathogens
- PhenoMATRIX™ for WASPLab®: AI for Sample Interpretation & Sorting
- BIOFIRE® FILMARRAY® Pneumonia Panels Gain FDA clearance and CE Marking
- bioMérieux and DIAGNOSTICS IS POWER at ECCMID 2018
- FDA Clears Identification of Mycobacteria, Nocardia and Moulds on VITEK® MS
- FDA Clearance for BacT/ALERT® VIRTUO™ Fully Automated Blood Culture System
- bioMérieux Your Expert in Infectious Diseases at ECCMID 2017
- bioMérieux Awarded Multi-year Agreement with NHS for Bacterial Screening of Platelets